Ludwig Enterprises, INC 8-K filings

Ludwig Enterprises, Inc. has secured $250,000 in financing through a convertible promissory note and a common stock purchase warrant from Alumni Capital LP.

Ludwig Enterprises, Inc. announced the appointment of Jose Antonio Reyes as its Interim Chief Executive Officer, effective October 1, 2025.

Ludwig Enterprises, Inc. announced the immediate appointment of Corain McGinn, an experienced executive and attorney, as an Independent Director to its Board.

Ludwig Enterprises, Inc. announced the resignation of its Chief Executive Officer, Charles T. Todd Jr., effective August 23, 2025, with a 30-day transition period.

Ludwig Enterprises, Inc. announced the appointment of Garth Lees-Rolfe, a seasoned finance and accounting professional with extensive biotech industry experience, as a new independent director to its Board.

Ludwig Enterprises, Inc. announced that Dr. Marvin S. Hausman has resigned from its Board of Directors, though he will continue in his role as Chief Scientific Officer, with no disagreements cited.

Ludwig Enterprises announced the publication of an abstract at the ASCO 2025 Annual Meeting detailing a novel, non-invasive breast cancer scanning test utilizing mRNA from buccal cells and machine learning.

Ludwig Enterprises, Inc. announces Revealia Breast, a non-invasive breast cancer screening test using a cheek swab and mRNA biomarker analysis, expected to launch in Q3 2025.

Ludwig Enterprises, Inc. appoints Charles T. Todd, Jr. as CEO and Chairman to lead the company's transition into a healthcare solutions provider, focusing on cancer diagnostics.

Marijuana, Inc. has acquired 100% of Exousia Ai, Inc. from Ludwig Enterprises, Inc. for $500,000, consisting of stock and a promissory note.

Ludwig Enterprises announces Revealia, an AI-driven cheek swab test designed for early cancer detection with continuously improving accuracy.

Ludwig Enterprises has acquired intellectual property related to mRNA neuro panels and serotonin assays, aiming to advance diagnostics for neurological conditions.

Ludwig Enterprises, Inc. has announced the resignation of Marvin S. Hausman, M.D. as CEO and the appointment of Jose Antonio Reyes as the new CEO, both effective immediately on August 20, 2024.

Ludwig Enterprises, Inc. is rebranding to Revealia, Inc. and plans to launch its cancer screening test, Revealia, in 2024.

Ludwig Enterprises has entered into a stock purchase agreement with an institutional investor, securing up to $5 million in funding and issuing warrants for additional shares.